Dec. 17 at 3:58 PM
$PACS no access to underlying JPM report yet, but out of all the firms that cover PACS, great to see them stick their neck out vs. one of the smaller, lesser known research shops.
$44 feels like a much more “real” price target that likely doesn’t include a now somewhat arbitrary discount related to PACS previous legal and compliance issues.
Will follow up with any interesting commentary once I have it.